Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Antibodies to SARS-CoV-2 and Their Potential for Therapeutic Passive Immunization

Version 1 : Received: 17 April 2020 / Approved: 19 April 2020 / Online: 19 April 2020 (04:52:17 CEST)

A peer-reviewed article of this Preprint also exists.

Klasse PJ, Moore JP. Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization. Elife. 2020;9:e57877. Published 2020 Jun 23. doi:10.7554/eLife.57877 Klasse PJ, Moore JP. Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization. Elife. 2020;9:e57877. Published 2020 Jun 23. doi:10.7554/eLife.57877

Journal reference: Elife 2020, 9, e57877
DOI: 10.7554/eLife.57877

Abstract

We review aspects of the antibody response to SARS-CoV-2, the causative agent of the COVID- 19 pandemic. The topics we cover are relevant to immunotherapy with plasma from recovered patients and with monoclonal antibodies against the viral S-protein. The development of vaccines against SARS-CoV-2, an essential public health tool, will also be informed by an understanding of the antibody response in infected patients. Although virus-neutralizing antibodies are likely to protect, antibodies could potentially trigger immunopathogenic events in SARS-CoV-2-infected patients or enhance infection. An awareness of these possibilities may benefit clinicians and the developers of antibody-based therapies and vaccines.

Subject Areas

SARS-CoV-2; COVID-19; neutralizing antibodies; immunotherapy; vaccine

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.